Alnylam Pharmaceuticals Reports Net Income In Q4

Alnylam Pharmaceuticals posted a strong finish to the year, swinging to profitability in the fourth quarter on the back of sharply higher product sales. The company reported net income of $111.5 million, a notable turnaround from a loss in the same period last year, alongside substantial growth in both total revenue and net product revenue.

Quarter Highlights

• Net income: $111.5 million, compared with a loss of $83.8 million in the prior-year quarter.
• GAAP earnings per share: $0.82, versus a loss of $0.65 a year ago.
• Non-GAAP earnings per share: $1.25, up from $0.06 in the prior-year period.
• Total revenues: $1.10 billion, up from $593.17 million year over year.
• Total net product revenues: $994.7 million, compared with $450.8 million a year earlier.

Outlook

For 2026, Alnylam projects total net product revenues in the range of $4.9 billion to $5.3 billion, reflecting confidence in the durability of its commercial portfolio and anticipated demand trends.

Market Reaction

In pre-market trading on the NasdaqGS, Alnylam shares were down 2.1% to $315.00 following the release.

The quarter’s results underscore significant operational momentum, with product sales serving as the primary growth engine. The shift to profitability, alongside a strong non-GAAP performance, highlights improving scale and execution as the company advances its commercial therapies. The guidance for 2026 suggests continued expansion, though investor focus may remain on uptake dynamics, margins, and pipeline milestones through the year.